While 2020 was clearly a busier year for grants and nonprofit deals with biopharma companies, pandemic efforts continue to drive the activity in these two areas. Through mid-July, there have been 204 grants valued at $1.75 billion, and 516 bio/nonprofit deals worth more than $8 billion, up from $4.66 billion only a month ago.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Antares, Ascletis, Biovaxys, Erytech, Index, GBT, Humanigen, Merck & Co., Pfizer, Radius, Rational Vaccines, Sorrento.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: 908 Devices, Accuray, Biocrucible, CM Life Sciences, Daxor, Concordance Healthcare Solutions, Dermtech, Gemspring Capital Management, Grail, Graphenedx, Illumina, Invivoscribe, Koko, Kkr, Longuevue Capital, Lucid Diagnostics, Medical Microinstruments, Nanalysis, One Moon Scientific, Pacemate, Pavmed, RBC Medical Innovations, Relay Medical, Sema4, Starfish Medical, Transcenta, Twist Bioscience, Upscripthealth, Visualdx, Zavation Medical Products.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Albireo, Ascentage, Astellas, Bluebird, Direct, Genentech, Inozyme, Magenta, Merck & Co., Organicell, Rarestone, Viracta.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aprea, Biomarin, Dicerna, Eureka, Immunomolecular, Lumos, Scilex, Sorrento, Takeda.
LONDON – The U.K. Medicines and Healthcare products Agency (MHRA) has embarked on wide-ranging reforms that are designed to make the most of post-Brexit regulatory flexibility while capitalizing on the ‘spirit of the pandemic,’ which has seen it rise to the occasion in supporting rapid set up of large-scale randomized clinical trials and approvals of COVID-19 vaccines.
While regulators and policymakers across the world are stressing the need for equitable access to COVID-19 vaccines, therapies and devices, their own policies and regulations may be getting in the way of that goal. The World Trade Organization (WTO) released a list of trade-related bottlenecks July 20 that are hindering access to pandemic-related medical products.
Stock market exuberance, particularly in favor of an innovative industry working to pull the world out of the deadly COVID-19 pandemic, led to drug developers shares surging 30% in 2020. But if one thing is certain, it is this: Markets usually pull back and that is partially why BioWorld’s Drug Developers Index is showing only a 2.06% gain so far this year, in contrast to both the Nasdaq Biotechnology Index and the Dow Jones Industrial Average, which are up 6.28% and 10.96%, respectively.
RSS
